Skip to main content
SpringerLink
Log in

Hodgkin’s Lymphoma

  • Chapter
  • First Online:
Handbook of Evidence-Based Radiation Oncology

  • 2694 Accesses

Abstract

This chapter will discuss the epidemiology, workup, and management of Hodgkin’s lymphoma, with an emphasis on external beam radiotherapy technique and published evidence.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Advani R, Maeda L, Lavori P, et al. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin’s disease. J Clin Oncol. 2007;25(25):3902–7.

    Article  Google Scholar 

  • Advani R, Horning SJ, Jonathan E, et al. Abbreviated 8-week chemotherapy (CT) plus involved node radiotherapy (INRT) for nonbulky stage I-II Hodgkin lymphoma: preliminary results of the Stanford G5 Study. J Clin Oncol (Meeting abstracts). 2011;29:8064.

    Article  Google Scholar 

  • Aleman BM, Raemaekers JM, Tomasic R, et al. Involved field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 2007;67(1):19–30.

    Article  Google Scholar 

  • Aleman BMP, Raemaekers JMM, Tirelli U, et al. Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med. 2003;348:2396–406.

    Article  Google Scholar 

  • Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol. 2004;22(14):2835–41.

    Article  Google Scholar 

  • Borchmann P, Haverkamp H, Diehl V, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol. 2011;29:4234–42.

    Article  CAS  Google Scholar 

  • Borchmann P, Haverkamp H, Diehl V, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol. 2011;29:4234–42.

    Article  CAS  Google Scholar 

  • Borchmann P, Haverkamp H, Lohri A, et al. Addition of rituximab to BEACOPP escalated to improve the outcome of early interim PET positive advanced stage Hodgkin lymphoma patients: second planned interim analysis of the HD18 study. Blood (Meeting abstracts). 2014;124:500.

    Google Scholar 

  • Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478–84.

    Article  CAS  Google Scholar 

  • Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin’s disease trial. N Engl J Med. 2002;346:1417–8.

    Article  Google Scholar 

  • Diefenbach CS, Li H, Hong F, et al. Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. Br J Haematol. 2015;171:530–8.

    Article  CAS  Google Scholar 

  • Diehl V, Brillant C, Engert A, et al. HD10: investigating reduction of combined modality treatment intensity in early stage Hodgkin’s lymphoma. Interim analysis of a randomized trial of the German Hodgkin Study Group (GHSG). J Clin Oncol (Meeting abstracts). 2005a;23:6506.

    Article  Google Scholar 

  • Diehl V, Brillant C, Engert A, et al. Recent interim analysis of the HD11 trial of the GHSG: intensification of chemotherapy and reduction of radiation dose in early unfavorable stage Hodgkin’s lymphoma. Blood. 2005b;106:abstract no. 816.

    Google Scholar 

  • Diehl V, Franklin J, Pfistner B, et al. Ten-year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). J Clin Oncol (Meeting abstracts). 2007a;25:LBA8015.

    Google Scholar 

  • Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. NEJM. 2003;348:2386–95.

    Article  CAS  Google Scholar 

  • Diehl V, Franklin J, Tesch H, et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin’s disease in the HD9 trial of the German Hodgkin’s Lymphoma Study Group (GHSG). Proc ASCO. 2007;8544:(abstract no. 7).

    Google Scholar 

  • Diehl V, Haverkamp H, Mueller R, et al. Eight cycles of BEACOPP escalated compared with 4 cycles of BEACOPP baseline with or without radiotherapy in patients in advanced stage Hodgkin lymphoma (HL): final analysis of the HD12 trial of the Germa Hodgkin Study Group (GHSG). J Clin Oncol. 2009;27:15s (Suppl; abstr 8544)

    Google Scholar 

  • Diehl V, Loeffler M, Pfreundschuh M, et al. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin’s disease. German Hodgkins’ Study Group (GHSG). Ann Oncol. 1995;6(9):901–10.

    Article  CAS  Google Scholar 

  • Eich H, Gossmann A, Engert A, et al. A contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin’s lymphoma – analysis of a quality control program initiated by the radiotherapy reference Center of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys. 2007;69:1187–92.

    Article  Google Scholar 

  • Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28:4199–206.

    Article  Google Scholar 

  • Eichenauer DA, Plütschow A, Fuchs M, von Tresckow B, Böll B, Behringer K, Diehl V, Eich HT, Borchmann P, Engert A. Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. J Clin Oncol. 2015;33(26):2857–62.

    Article  CAS  Google Scholar 

  • Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Král Z, Fuchs M, Hallek M, Kanz L. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791–9.

    Article  CAS  Google Scholar 

  • Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27(27):4548–54.

    Article  Google Scholar 

  • Engert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: final results of the GHSG HD7 trial. J Clin Oncol. 2007;25(23):3495–502.

    Article  CAS  Google Scholar 

  • Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363:640–52.

    Article  CAS  Google Scholar 

  • Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, de Wit M, Mezger J, Dühmke E, Willich N. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 2003;21 (19):3601–8.

    Article  Google Scholar 

  • Fabian CJ, Mansfield CM, Dahlberg S, et al. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study. Ann Intern Med. 1994;120(11):903–12.

    Article  CAS  Google Scholar 

  • Ferme C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med. 2007;357(19):1916–27.

    Article  CAS  Google Scholar 

  • Firme C, Sebban C, Hennequin C, et al. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin’s disease: results of the Groupe d’etudes des Lymphomes de l’Adulte H89 trial. Blood. 2000;95:2246–52.

    Google Scholar 

  • Gallmini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746–52.

    Article  Google Scholar 

  • Girinsky T, Specht L, Ghalibafian M, et al. The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol. 2008;88:202–10.

    Article  Google Scholar 

  • Gobbi PG, Levis A, Chisesi T, et al. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced stage Hodgkin’s lymphoma. Final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol. 2005;23:9198–207.

    Article  CAS  Google Scholar 

  • Hasenclever D, Diehl V, Armitage JO, et al. A prognostic score for advanced Hodgkin’s disease. N Engl J Med. 1998;339:1506–14.

    Article  CAS  Google Scholar 

  • Hay AE, Klimm B, Chen BE, Goergen H, Shepherd LE, Fuchs M, Gospodarowicz MK, Borchmann P, Connors JM, Markova J, Crump M. An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma. Ann Oncol. 2013;24(12):3065–9.

    Article  CAS  Google Scholar 

  • Horning SJ, Hoppe RT, Advani R, et al. Efficacy and late effects of Stanford V chemotherapy and radiotherapy in untreated Hodgkin’s disease: mature data in early and advanced stage patients. Blood. 2004;104:308 (abstr 308).

    Google Scholar 

  • Johnson PW, Sydes MR, Hancock BW, Cullen M, Radford JA, Stenning SP. Consolidation radiotherapy in patients with advanced Hodgkin’s lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). J Clin Oncol. 2010;28(20):3352–9.

    Article  Google Scholar 

  • Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee on International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571–8.

    Article  Google Scholar 

  • Khan N, Khan MK, Almasan A, Singh AD, Macklis R. The evolving role of radiation therapy in the management of malignant melanoma. Int J Radiat Oncol Biol Phys. 2011;80(3):645–54.

    Article  Google Scholar 

  • Kobe C, Dietlein M, Franklin J, et al. FDG-PET for assessment of residual tissue after completion of chemotherapy in Hodgkin lymphoma – report on the second interim analysis of the PET investigation in the trial HD15 of the GHSG. Haematol. 2007;92(Suppl 5):CO21.

    Google Scholar 

  • Laskar S, Gupta T, Vimal S, et al. Consolidation radiation after complete remission in Hodgkin’s disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol. 2004;22:62–8.

    Article  CAS  Google Scholar 

  • Lavoie JC, Connors JM, Phillips GL, et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood. 2005;106(4):1473–8.

    Article  CAS  Google Scholar 

  • Levis M, Piva C, Filippi AR, Botto B, Gavarotti P, Pregno P, Nicolosi M, Freilone R, Parvis G, Gottardi D, Vitolo U. Potential benefit of involved-field radiotherapy for patients with relapsed-refractory hodgkin’s lymphoma with incomplete response before autologous stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2017;17(1):14–22.

    Article  Google Scholar 

  • Macdonald DA, Ding K, Gospodarowicz MK, et al. Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma. Ann Oncol. 2007;18(10):1680–4.

    Article  CAS  Google Scholar 

  • Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76:S10–9.

    Article  Google Scholar 

  • Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med. 2012;366:399–408.

    Article  CAS  Google Scholar 

  • Noordijk E, Carde P, Hagenbeek A. Combination of radiotherapy and chemotherapy is advisable in all patients with clinical stage I-II Hodgkin’s disease. Six-year results of the EORTC-GPMC controlled clinical trials “H7-VF”, “H7-F” and “H7-U”. Presented at ASTRO 1997.

    Google Scholar 

  • Noordijk EM, Thomas J, Ferme C, et al. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (HL). J Clin Oncol (Meeting abstracts). 2005;23:6505.

    Article  Google Scholar 

  • Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European Organization for Research and Treatment of Cancer (EORTC) H7 randomized controlled trials. J Clin Oncol. 2006;24:3128–35.

    Article  Google Scholar 

  • Olszewski AJ, Shrestha R, Castillo JJ. Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: analysis of the National Cancer Data Base. J Clin Oncol. 2015;33(6):625–33.

    Article  Google Scholar 

  • Pavlovsky S, Maschio M, Santarelli MT, et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I–II Hodgkin’s disease. J Natl Cancer Inst. 1988;80(18):1466–73.

    Article  CAS  Google Scholar 

  • Picardi M, De Renzo A, Pane F, et al. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin’s lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma. 2007;48(9):1721–7.

    Article  Google Scholar 

  • Poen JC, Hoppe RT, Horning SJ. High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin’s disease: the impact of involved field radiotherapy on patterns of failure and survival. Int J Radiat Oncol Biol Phys. 1996;36(1):3–12.

    Article  CAS  Google Scholar 

  • Press OW, LeBlanc M, Lichter AS, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin’s disease. J Clin Oncol. 2001;19:4238–44.

    Article  CAS  Google Scholar 

  • Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372:1598–607.

    Article  CAS  Google Scholar 

  • Raemaekers JMM, Andre MPE, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014;32:1188–94.

    Article  Google Scholar 

  • Rigacci L, Vitolo U, Nassi L, et al. Positron emission tomography in the staging of patients with Hodgkin’s lymphoma. Ann Hematol. 2007;86:897–903.

    Article  Google Scholar 

  • Schaapveld M, Aleman BMP, van Eggermond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Engl J Med. 2015;373:2499–511.

    Article  CAS  Google Scholar 

  • Shimabukuro-Vornhagen A, Haverkamp H, Engert A, et al. Lymphocyte-rich classical Hodgkin’s lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin’s Study Group trials. J Clin Oncol. 2005;23:5739–45.

    Article  Google Scholar 

  • Sickinger MT, von Tresckow B, Kobe C, et al. PET-adapted omission of radiotherapy in early stage Hodgkin lymphoma—a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2016;101:86–92.

    Article  Google Scholar 

  • Sieber M, Franklin J, Tesch H. Two cycles ABVD plus extended field radiotherapy is superior to radiotherapy alone in early stage Hodgkin’s disease: results of the German Hodgkin’s Lymphoma Study Group (GHSG) trial HD7. Leuk Lymphoma. 2002;43(Suppl 2):52.

    Google Scholar 

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.

    Article  Google Scholar 

  • Sieniawski M, Franklin J, Nogova L, et al. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin’s lymphoma. J Clin Oncol. 2007;25(15):2000–5.

    Article  Google Scholar 

  • Specht L, Gray RG, Clarke MJ, et al. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin’s disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin’s Disease Collaborative Group. J Clin Oncol. 1998;16:830–43.

    Article  CAS  Google Scholar 

  • Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol. 2014;89:854–62.

    Article  Google Scholar 

  • Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004;104:3483–9.

    Article  CAS  Google Scholar 

  • Thomas J, Ferme C, Noordijk EM, et al. EORTC lymphoma group; groupe d’études des lymphomes adultes (GELA). Results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (HL). Haematologica. 2007;92(s5):27.

    Google Scholar 

  • van Nimwegen FA, Schaapveld M, Cutter DJ, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol. 2015;34(3):235–43.

    Article  Google Scholar 

Download references

Acknowledgment

We thank Hans T. Chung MD, Stephen L. Shiao MD, PhD, and Naomi R. Schechter MD for their work on the prior edition of this chapter.

Author information

Authors and Affiliations

  1. Radiation Oncology, University of California San Francisco, San Francisco, CA, USA

    Jason Chan & Steve E. Braunstein

Authors
  1. Jason Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steve E. Braunstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steve E. Braunstein .

Editor information

Editors and Affiliations

  1. The Oregon Clinic, Providence St. Vincent Medical Center, Portland, OR, USA

    Eric K. Hansen

  2. Department of Radiation Oncology, University of California, San Franc, SAN FRANCISCO, CA, USA

    Mack Roach III

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Chan, J., Braunstein, S.E. (2018). Hodgkin’s Lymphoma. In: Hansen, E., Roach III, M. (eds) Handbook of Evidence-Based Radiation Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-62642-0_35

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-62642-0_35

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-62641-3

  • Online ISBN: 978-3-319-62642-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation